FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W323341750> ?p ?o ?g. }

• W323341750 endingPage "1157" @default.
• W323341750 startingPage "1149" @default.
• W323341750 abstract "Abstract The toxicity of autologous bone marrow transplantation (ABMT) is correlated to neutropenia. Although recombinant human granulocyte- macrophage colony-stimulating factor (rhu GM-CSF) seems to hold promise in accelerating neutrophil recovery, few analyses from randomized studies are presently available. Ninety-one patients with non-Hodgkin's lymphoma receiving high-dose ablative chemotherapy followed by ABMT with unpurged or purged marrow were included in a randomized, double- blind, placebo-controlled trial. Forty-four patients received 250 micrograms rhu GM-CSF (Escherichia coli)/m2 and 47 patients received placebo. Treatment was administered daily as continuous infusion from day of ABMT until the absolute neutrophil count (ANC) reached 0.5 x 10(9)/L for 7 days or until day 30, whichever was first. With rhu GM- CSF, 50% of the patients reached an ANC count greater than 0.5 x 10(9)/L at day 14 as opposed to day 21 with placebo (P less than .0001). Patients transplanted with marrow purged by mafosfamide also recovered earlier when treated with rhu GM-CSF (16 v 20.5 days, P = .013). The hospitalization duration was shorter in the rhu GM-CSF group (median, 23 v 28 days, P less than .05). No difference was observed in fever, number of infections, and antibiotic administration between the two groups. The major adverse event ascribed to rhu GM-CSF was a capillary leak syndrome in three patients graded as severe in two patients, moderate in one, and reversible in all three patients. In addition, one patient in the rhu GM-CSF group died suddenly with no explanation. In long term follow-up, the relapse rate was identical in both groups and there was no significant difference in the number of deaths at 1 year (12 with rhu GM-CSF v 9 with placebo), although deaths seemed to occur slightly earlier in the rhu GM-CSF group. We conclude that after ABMT with purged or unpurged marrow, rhu GM-CSF (E coli) significantly reduces neutropenia duration and hospitalization stay. A positive causative relation between the study drug and/or its mode of application with an increased toxicity as compared with GM-CSF from other sources and/or other modes of application cannot be deduced from the experiences in this study. Additional randomized trials would be necessary for an appropriate answer." @default.
• W323341750 created "2016-06-24" @default.
• W323341750 creator A5005071483 @default.
• W323341750 creator A5012219088 @default.
• W323341750 creator A5022864146 @default.
• W323341750 creator A5025226777 @default.
• W323341750 creator A5034534124 @default.
• W323341750 creator A5043616696 @default.
• W323341750 creator A5058365219 @default.
• W323341750 creator A5063900927 @default.
• W323341750 creator A5082518780 @default.
• W323341750 creator A5084447104 @default.
• W323341750 date "1992-09-01" @default.
• W323341750 modified "2023-10-16" @default.
• W323341750 title "Recombinant human granulocyte-macrophage colony-stimulating factor after high-dose chemotherapy and autologous bone marrow transplantation with unpurged and purged marrow in non-Hodgkin's lymphoma: a double- blind placebo-controlled trial" @default.
• W323341750 cites W100306417 @default.
• W323341750 cites W1830589476 @default.
• W323341750 cites W1970116774 @default.
• W323341750 cites W1999896050 @default.
• W323341750 cites W2007848599 @default.
• W323341750 cites W200860116 @default.
• W323341750 cites W2031588848 @default.
• W323341750 cites W2033093905 @default.
• W323341750 cites W2036631709 @default.
• W323341750 cites W2044352014 @default.
• W323341750 cites W2045957427 @default.
• W323341750 cites W2047747212 @default.
• W323341750 cites W2058657134 @default.
• W323341750 cites W2083427077 @default.
• W323341750 cites W2088417905 @default.
• W323341750 cites W2089978497 @default.
• W323341750 cites W2090635877 @default.
• W323341750 cites W2096104385 @default.
• W323341750 cites W2097779050 @default.
• W323341750 cites W2122522483 @default.
• W323341750 cites W2138561513 @default.
• W323341750 cites W2146032483 @default.
• W323341750 cites W2219538991 @default.
• W323341750 cites W2260618113 @default.
• W323341750 cites W2278794586 @default.
• W323341750 cites W2313423582 @default.
• W323341750 cites W2313477330 @default.
• W323341750 cites W2317007280 @default.
• W323341750 cites W2336413723 @default.
• W323341750 cites W2337660074 @default.
• W323341750 cites W2339381415 @default.
• W323341750 cites W2339709756 @default.
• W323341750 cites W2343527457 @default.
• W323341750 cites W2408176001 @default.
• W323341750 cites W241455346 @default.
• W323341750 cites W2418360152 @default.
• W323341750 cites W2593892363 @default.
• W323341750 cites W259525224 @default.
• W323341750 cites W2606386549 @default.
• W323341750 cites W285184416 @default.
• W323341750 doi "https://doi.org/10.1182/blood.v80.5.1149.1149" @default.
• W323341750 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/1515637" @default.
• W323341750 hasPublicationYear "1992" @default.
• W323341750 type Work @default.
• W323341750 sameAs 323341750 @default.
• W323341750 citedByCount "104" @default.
• W323341750 countsByYear W3233417502013 @default.
• W323341750 countsByYear W3233417502014 @default.
• W323341750 countsByYear W3233417502015 @default.
• W323341750 countsByYear W3233417502016 @default.
• W323341750 countsByYear W3233417502019 @default.
• W323341750 crossrefType "journal-article" @default.
• W323341750 hasAuthorship W323341750A5005071483 @default.
• W323341750 hasAuthorship W323341750A5012219088 @default.
• W323341750 hasAuthorship W323341750A5022864146 @default.
• W323341750 hasAuthorship W323341750A5025226777 @default.
• W323341750 hasAuthorship W323341750A5034534124 @default.
• W323341750 hasAuthorship W323341750A5043616696 @default.
• W323341750 hasAuthorship W323341750A5058365219 @default.
• W323341750 hasAuthorship W323341750A5063900927 @default.
• W323341750 hasAuthorship W323341750A5082518780 @default.
• W323341750 hasAuthorship W323341750A5084447104 @default.
• W323341750 hasBestOaLocation W3233417501 @default.
• W323341750 hasConcept C126322002 @default.
• W323341750 hasConcept C141071460 @default.
• W323341750 hasConcept C142724271 @default.
• W323341750 hasConcept C168563851 @default.
• W323341750 hasConcept C197934379 @default.
• W323341750 hasConcept C204787440 @default.
• W323341750 hasConcept C27081682 @default.
• W323341750 hasConcept C2776694085 @default.
• W323341750 hasConcept C2777063308 @default.
• W323341750 hasConcept C2777478134 @default.
• W323341750 hasConcept C2777767877 @default.
• W323341750 hasConcept C2778690821 @default.
• W323341750 hasConcept C2779338263 @default.
• W323341750 hasConcept C2780007613 @default.
• W323341750 hasConcept C2911091166 @default.
• W323341750 hasConcept C71924100 @default.
• W323341750 hasConcept C74133956 @default.
• W323341750 hasConcept C90924648 @default.
• W323341750 hasConceptScore W323341750C126322002 @default.
• W323341750 hasConceptScore W323341750C141071460 @default.

• next